Table 2. Risk factors for the development of renal adverse events in univariable analysis.
| Variable | β | OR (95% CI) | P value |
|---|---|---|---|
| Gender | 0.039 | 1.038 (0.456–2.369) | 0.927 |
| Age | 0.000 | 1.0 (0.966–1.036) | 0.99 |
| SCLC | 0.697 | 2.008 (0.851–4.736) | 0.111 |
| PS | 0.149 | 1.161 (0.562–2.397) | 0.687 |
| Other irAEs | 0.341 | 1.406 (0.608–3.251) | 0.426 |
| Hypertension | 0.616 | 1.851 (0.946–3.623) | 0.072 |
| Coronary heart disease | 0.961 | 2.614 (1.025–6.668) | 0.044 |
| Diabetes | 0.000 | 1.0 (0.393–2.542) | 1.0 |
| COPD | 0.606 | 1.833 (0.733–4.579) | 0.195 |
| Distant metastasis | 0.641 | 1.899 (0.985–3.661) | 0.056 |
| Cycles of ICI therapy | 0.019 | 1.109 (0.988–1.051) | 0.228 |
| Combo ICIs and antiangiogenic | −0.784 | 0.456 (0.058–3.564) | 0.455 |
| Combo ICIs and chemotherapy | 0.138 | 1.148 (0.593–2.222) | 0.682 |
| PD-L1 | 0.34 | 1.417 (0.551–3.639) | 0.469 |
| PD-1 | −0.348 | 0.706 (0.275–1.813) | 0.469 |
| First-line of ICI therapy | 0.171 | 1.187 (0.614–2.293) | 0.611 |
| Creatinine | 0.001 | 1.001 (0.986–1.018) | 0.856 |
| eGFR | 0.000 | 1.0 (0.993–1.007) | 0.929 |
| Uric acid | 0.001 | 1.001 (0.997–1.004) | 0.736 |
| Albumin | 0.006 | 1.006 (0.949–1.067) | 0.829 |
| Hemoglobin | −0.003 | 0.997 (0.983–1.011) | 0.688 |
| ANC | −0.063 | 0.939 (0.834–1.057) | 0.296 |
| AEC | −0.51 | 0.6 (0.073–4.939) | 0.635 |
| AMC | −1.817 | 0.162 (0.03–0.868) | 0.034 |
| ALC | −0.042 | 0.959 (0.54–1.705) | 0.886 |
| NLR | 0.0 | 1 (0.926–1.081) | 0.991 |
| LMR | 0.129 | 1.138 (1.003–1.29) | 0.044 |
| PLR | 0.0 | 1.0 (0.99–1002) | 0.714 |
| PIV | 0.0 | 1.0 (0.99–1.0) | 0.48 |
| CD3 | 0.0 | 1.0 (0.99–1.001) | 0.659 |
| CD4 | 0.0 | 1.0 (0.99–1.001) | 0.907 |
| CD8 | 0.0 | 1.0 (0.998–1.002) | 0.991 |
| IL-6 | −0.004 | 0.996 (0.985–1.007) | 0.496 |
| IL-8 | 0.0 | 1.0 (0.999–1.001) | 0.842 |
| IL-10 | −0.088 | 0.915 (0.741–1.13) | 0.411 |
| C3 | −1.006 | 0.366 (0.066–2.038) | 0.251 |
| C4 | −3.145 | 0.043 (0.001–1.557) | 0.086 |
| ANA positive | −0.017 | 0.983 (0.46–2.101) | 0.964 |
SCLC, small cell lung cancer; PS, performance status; irAEs, immune-related adverse events; COPD, chronic obstructive pulmonary disease; ICI, immune checkpoints inhibitor; ANC, absolute neutrophil count; AEC, absolute eosinophils count; AMC, absolute monocyte count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; LMR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; PIV, Pan immune and inflammation value; C3, complement C3; C4, complement C4; ANA, antinuclear antibody.